Guardado en:

0121-5426

2538-9513

33

2021-10-13

6

18

http://purl.org/coar/access_right/c_abf2

info:eu-repo/semantics/openAccess

id f71c693f3d15078eefff78dc62388ad7
record_format ojs
spelling Publication
Casallas Gómez, Alvaro
Text
http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
http://purl.org/coar/version/c_970fb48d4fbd8a85
info:eu-repo/semantics/publishedVersion
http://purl.org/redcol/resource_type/ARTREF
http://purl.org/coar/resource_type/c_6501
info:eu-repo/semantics/article
https://creativecommons.org/licenses/by-nc-sa/4.0/
Español
https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/547
Revista Colombiana de Neumología
Asociación Colombiana de Neumología y Cirugía de Tórax
application/pdf
Artículo de revista
cáncer pulmonar
adenocarcinoma
inmunohistoquímica
1
33
biología tumoral
genética
biopsias líquidas
immunohistochemistry
lung cancer
adenocarcinoma
tumor biology
genetics
Journal article
liquid biopsies
Lung cancer represented the second leading cause of cancer and the leading cause of cancer mortality in the United States by 2020. In 2016, 538,000 lung cancer cases were reported, with 80,775 men and 68,096 women dying in the same year. The five-year survival rate of 15.6 % in 2011 rose to 19.4 % in 2019, probably associated with a decrease in smokers, mainly due to advances in targeted pharmacological therapies and the development of immunotherapies. Pulmonary adenocarcinoma, particularly in young, nonsmoking women, has shown an increased incidence. However, survival in this population has had significant advances associated with a better, updated understanding of identifiable biological and genetic mechanisms in lung cancer and a better classification of these tumors into types and subtypes. Numerous advances in immunohistochemical techniques (in the diagnosis and classification of lung cancer and selection of cases for molecular analysis) and the knowledge of genomic alterations associated with various lung cancer types have changed their treatment approach, especially in advanced stages of tumorigenesis. Oncogenes and tumor suppressor genes have been identified, making possible the development of novel therapeutic agents with a well-defined, focused target and immunotherapy as an additional therapeutic option for this pathology. This review is intended to provide a straightforward guide to the tumor architecture (immunohistochemistry and molecular analysis) of lung cancer in its most common types.
https://doi.org/10.30789/rcneumologia.v33.n1.2021.547
6
18
https://revistas.asoneumocito.org/index.php/rcneumologia/article/download/547/475
10.30789/rcneumologia.v33.n1.2021.547
2538-9513
0121-5426
2021-10-13
2021-10-13T16:17:57Z
2021-10-13T16:17:57Z
institution ASOCIACION COLOMBIANA DE NEUMOLOGIA Y CIRUGIA DE TORAX
thumbnail https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADENEUMOLOGIAYCIRUGIADETORAX/logo.png
country_str Colombia
collection Revista Colombiana de Neumología
description_eng Lung cancer represented the second leading cause of cancer and the leading cause of cancer mortality in the United States by 2020. In 2016, 538,000 lung cancer cases were reported, with 80,775 men and 68,096 women dying in the same year. The five-year survival rate of 15.6 % in 2011 rose to 19.4 % in 2019, probably associated with a decrease in smokers, mainly due to advances in targeted pharmacological therapies and the development of immunotherapies. Pulmonary adenocarcinoma, particularly in young, nonsmoking women, has shown an increased incidence. However, survival in this population has had significant advances associated with a better, updated understanding of identifiable biological and genetic mechanisms in lung cancer and a better classification of these tumors into types and subtypes. Numerous advances in immunohistochemical techniques (in the diagnosis and classification of lung cancer and selection of cases for molecular analysis) and the knowledge of genomic alterations associated with various lung cancer types have changed their treatment approach, especially in advanced stages of tumorigenesis. Oncogenes and tumor suppressor genes have been identified, making possible the development of novel therapeutic agents with a well-defined, focused target and immunotherapy as an additional therapeutic option for this pathology. This review is intended to provide a straightforward guide to the tumor architecture (immunohistochemistry and molecular analysis) of lung cancer in its most common types.
author Casallas Gómez, Alvaro
spellingShingle Casallas Gómez, Alvaro
cáncer pulmonar
adenocarcinoma
inmunohistoquímica
biología tumoral
genética
biopsias líquidas
immunohistochemistry
lung cancer
adenocarcinoma
tumor biology
genetics
liquid biopsies
author_facet Casallas Gómez, Alvaro
topicspa_str_mv cáncer pulmonar
adenocarcinoma
inmunohistoquímica
biología tumoral
genética
biopsias líquidas
topic cáncer pulmonar
adenocarcinoma
inmunohistoquímica
biología tumoral
genética
biopsias líquidas
immunohistochemistry
lung cancer
adenocarcinoma
tumor biology
genetics
liquid biopsies
topic_facet cáncer pulmonar
adenocarcinoma
inmunohistoquímica
biología tumoral
genética
biopsias líquidas
immunohistochemistry
lung cancer
adenocarcinoma
tumor biology
genetics
liquid biopsies
citationvolume 33
citationissue 1
publisher Asociación Colombiana de Neumología y Cirugía de Tórax
ispartofjournal Revista Colombiana de Neumología
source https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/547
language Español
format Article
rights http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
type_driver info:eu-repo/semantics/article
type_coar http://purl.org/coar/resource_type/c_6501
type_version info:eu-repo/semantics/publishedVersion
type_coarversion http://purl.org/coar/version/c_970fb48d4fbd8a85
type_content Text
publishDate 2021-10-13
date_accessioned 2021-10-13T16:17:57Z
date_available 2021-10-13T16:17:57Z
url https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/547
url_doi https://doi.org/10.30789/rcneumologia.v33.n1.2021.547
issn 0121-5426
eissn 2538-9513
doi 10.30789/rcneumologia.v33.n1.2021.547
citationstartpage 6
citationendpage 18
url2_str_mv https://revistas.asoneumocito.org/index.php/rcneumologia/article/download/547/475
_version_ 1797159634701647872